Original Article
A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis
Análisis de las consecuencias en materia de costos del uso preferencial del secukinumab en comparación con el adalimumab para el tratamiento de la artritis psoriásica
Read
3397
Timeswas read the article
1230
Total PDF
2167
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 April | 100 | 42 | 142 |
| 2025 March | 101 | 34 | 135 |
| 2025 February | 87 | 27 | 114 |
| 2025 January | 67 | 46 | 113 |
| 2024 December | 42 | 32 | 74 |
| 2024 November | 82 | 69 | 151 |
| 2024 October | 61 | 37 | 98 |
| 2024 September | 79 | 31 | 110 |
| 2024 August | 64 | 44 | 108 |
| 2024 July | 76 | 38 | 114 |
| 2024 June | 59 | 42 | 101 |
| 2024 May | 62 | 40 | 102 |
| 2024 April | 40 | 21 | 61 |
| 2024 March | 42 | 30 | 72 |
| 2024 February | 36 | 32 | 68 |
| 2024 January | 31 | 32 | 63 |
| 2023 December | 41 | 32 | 73 |
| 2023 November | 42 | 39 | 81 |
| 2023 October | 44 | 29 | 73 |
| 2023 September | 212 | 37 | 249 |
| 2023 August | 29 | 12 | 41 |
| 2023 July | 41 | 33 | 74 |
| 2023 June | 45 | 31 | 76 |
| 2023 May | 39 | 22 | 61 |
| 2023 April | 24 | 10 | 34 |
| 2023 March | 85 | 28 | 113 |
| 2023 February | 51 | 31 | 82 |
| 2023 January | 35 | 31 | 66 |
| 2022 December | 68 | 36 | 104 |
| 2022 November | 53 | 36 | 89 |
| 2022 October | 75 | 27 | 102 |
| 2022 September | 50 | 31 | 81 |
| 2022 August | 44 | 39 | 83 |
| 2022 July | 36 | 33 | 69 |
| 2022 June | 52 | 34 | 86 |
| 2022 May | 64 | 40 | 104 |
| 2022 February | 1 | 2 | 3 |
| 2022 January | 1 | 0 | 1 |
| 2021 November | 2 | 2 | 4 |
| 2021 October | 2 | 0 | 2 |
| 2021 May | 1 | 2 | 3 |
| 2021 April | 0 | 6 | 6 |
| 2021 March | 0 | 2 | 2 |
| 2021 January | 0 | 2 | 2 |
| 2020 November | 0 | 3 | 3 |
| 2020 September | 1 | 3 | 4 |
Show all
